WAYNE, Pa.--(BUSINESS WIRE)--Encorium Group, Inc. (Nasdaq: ENCO), a full-service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials and patient registries to many of the world’s leading pharmaceutical and biotechnology companies, today announced the signing of $3.5 million of new business contracts with a global biopharmaceutical company. These contracts, which cover clinical trials in the field of vaccines and infectious diseases, will be conducted in multiple European countries. Services include regulatory submissions, project management, and field monitoring. Revenue recognition will begin in the current quarter with the remainder expected to occur on a proportional performance basis as services are performed on each project.
